[
  {
    "ts": null,
    "headline": "Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe",
    "summary": "Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11The approval of this new therapeutic approach introduces an oral, 14-day treatment specifically indicated for PPDThe EC approval of ZURZUVAE is based on the SKYLARK study, which demonstrated rapid relief from depressive symptoms as early as day 3 and sustained through day 45 comp",
    "url": "https://finnhub.io/api/news?id=4fe4752a1c604e87e727c6956350bc43ae2b02c397d8b8d91a92232af5f769c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758144600,
      "headline": "Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe",
      "id": 136798013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11The approval of this new therapeutic approach introduces an oral, 14-day treatment specifically indicated for PPDThe EC approval of ZURZUVAE is based on the SKYLARK study, which demonstrated rapid relief from depressive symptoms as early as day 3 and sustained through day 45 comp",
      "url": "https://finnhub.io/api/news?id=4fe4752a1c604e87e727c6956350bc43ae2b02c397d8b8d91a92232af5f769c0"
    }
  },
  {
    "ts": null,
    "headline": "Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen (NASDAQ:BIIB).",
    "url": "https://finnhub.io/api/news?id=fb13b71be288485868231c977ba9f1c93fe601cdd1ee235627f91288b6fa7d57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758083470,
      "headline": "Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way",
      "id": 136789203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen (NASDAQ:BIIB).",
      "url": "https://finnhub.io/api/news?id=fb13b71be288485868231c977ba9f1c93fe601cdd1ee235627f91288b6fa7d57"
    }
  }
]